The FDA announced on Feb. 11, 2015, that Mylan Institutional LLC voluntarily recalled Doxorubicin Hydrochloride Injection due to a mispackaging hazard. The firm initiated the Class III recall after correctly labeled Ifosfamide Injection was placed in cartons labeled as Doxorubicin.
How to tell if you have it
- Brand: Mylan Institutional LLC
- Product: Doxorubicin Hydrochloride Injection, USP, 200 mg/100 mL (2 mg/mL)
- NDC: 53150-317-01
- Lot Number: 7801009
- Expiration Date: Apr-2015
The hazard
The hazard involves the correct labeled product being mispackaged. Specifically, Ifosfamide Injection 50 mg/mL, 60 mL, may have been placed in a carton labeled Doxorubicin Hydrochloride Injection 2 mg/mL, 100 mL.
Context
GovInfoNow's records show Mylan Institutional LLC has 10 other recalls on record since Jan. 23, 2015. Other recent recalls of similar products include Mylan Thiamine HCl Injection Recall (May 3, 2021), Mylan Amiodarone Injection Recall (Aug. 17, 2020), and Mylan Daptomycin Injection Recall (July 7, 2020). Other recent recalls of similar products include Mylan Mycophenolate Mofetil Injection Recall (July 2, 2026), Mylan Mycophenolate Mofetil Injections: Failed Dissolution Specifications (Aug. 26, 2026), and McKesson Gemcitabine Injection Recall (June 10, 2026).